Nooredit is a nootropic drug that stimulates memory consolidation, facilitates a learning process, increases brain tissue resistance to toxic effects, and has an anticonvulsant effect.

Nooredit contains the active ingredient fonturacetam, which is a drug used for for attention deficit hyperactivity disorder treatment. Fonturacetam has a positive impact on metabolic processes and brain blood circulation, increases brain tissue resistance to hypoxia (oxygen deprivation) and toxic effects, boosts mood, quickly relieves fatigue, drowsiness, and improves performance. It makes learning process easier, improves concentration and mental activity, eliminates memory impairment caused by various effects. 

The drug product is produced at Irkutsk enterprise of the Pharmasyntez Group of Companies. The granulation section of the Sterile Dosage Form department is equipped with the latest Swiss equipment. Аll products are manufactured in full compliance with GMP standards.

The second batch of the medication of 40,000 packages is planned to be released in December 2023

Nooredit has become the second nootropic drug in the Pharmasyntez portfolio. The company has been producing nootropic medication Nooaktiv which is used for ischemic stroke, traumatic brain injury, and cognitive impairment since 2022.